2 news items
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
MRK
28 May 24
. Triple-negative breast cancer tends to be more common in people who are younger than 40 years of age, who are Black or who have
The Most Important Catalyst For Merck's Stock In 2024 Could Be Sotatercept Launch, Analyst Says
MRK
27 Mar 24
that the label was better than anticipated. There is no Black Box, no Risk Evaluation and Mitigation Strategy (REMS), and only initial monitoring
- Prev
- 1
- Next